- Conditions
- Hepatitis C
- Interventions
- PREP-C
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 730
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab, Sorafenib, Ipilimumab, Cabozantinib
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more
- Conditions
- Hepato Cellular Carcinoma (HCC)
- Interventions
- BC3402, Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 180
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more
- Conditions
- Single Ventricle Heart Disease
- Interventions
- Udenafil
- Drug
- Lead sponsor
- Mezzion Pharma Co. Ltd
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 13 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Solid Tumor
- Interventions
- Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
- Drug
- Lead sponsor
- Miller Children's & Women's Hospital Long Beach
- Other
- Eligibility
- 12 Months to 31 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 2
- States / cities
- Long Beach, California • Orange, California
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Sorafenib, Yttrium-90 (Y-90)
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Prostate Cancer, Prostate Cancer
- Interventions
- 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
- Drug · Procedure · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metabolic Dysfunction Associated Steatohepatitis
- Interventions
- Survodutide, Placebo matching survodutide
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 126
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
- Conditions
- Immunology
- Interventions
- BMS-986020, [11C]BMT-136088
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cystic Fibrosis
- Interventions
- RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Patupilone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alcoholic Liver Disease, COVID 19 Pneumonia
- Interventions
- β-hydroxy β-methyl butyrate (HMB) enriched amino acid, Balanced amino acid
- Dietary Supplement
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Interventions
- Maralixibat, Placebo
- Drug · Other
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NASH
- Interventions
- AZD7503 Intervention
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
- Drug · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Aurora, Colorado • Gainesville, Florida • Orlando, Florida + 16 more
- Conditions
- Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2051
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pediatric Obesity, NAFLD, GERD
- Interventions
- Lansoprazole, Pantoprazole, Midazolam
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Advanced Malignant Solid Tumor, Solid Tumor Cancer
- Interventions
- PLT012
- Drug
- Lead sponsor
- Pilatus Biosciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Dallas, Texas • Houston, Texas
- Conditions
- Hepatitis C Virus, Liver Transplantation
- Interventions
- Not listed
- Lead sponsor
- Schiano, Thomas D., MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Cancer, Liver Tumor, Hepatocellular Carcinoma, Liver Carcinoma
- Interventions
- perflutren lipid microspheres, 3D ultrasound
- Drug · Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Liver Cirrhosis, Hepatic Cirrhosis, Portal Hypertension
- Interventions
- IDN-6556
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- West Haven, Connecticut • Washington D.C., District of Columbia • Miami, Florida + 10 more